Yu-Tzu Chang1, Tsai-Chieh Ling1, Ya-Yun Cheng2, Chien-Yao Sun1, Jia-Ling Wu1, Ching Hui Tai3, Jen-Ren Wang3,4, Junne-Ming Sung1. 1. Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan. 2. Department of Environmental Health, T.H Chan School of Public Health, Harvard University, Boston, MA 02115, USA. 3. Department of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan. 4. National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Tainan 704, Taiwan.
Abstract
BACKGROUND:Non-dialysis-dependent chronic kidney disease (CKD-ND) patients are recommended to receive a one-dose influenza vaccination annually. However, studies investigating vaccine efficacy in the CKD-ND population are still lacking. In this study, we aimed to evaluate vaccine efficacy between the one-dose and two-dose regimen and among patients with different stages of CKD throughout a 20-week follow-up period. METHODS: We conducted a single-center, non-randomized, open-label, controlled trial among patients with all stages of CKD-ND. Subjects were classified as unvaccinated, one-dose, and two-dose groups (4 weeks apart) after enrollment. Serial changes in immunological parameters (0, 4, 8, and 20 weeks after enrollment), including seroprotection, geometric mean titer (GMT), GMT fold-increase, seroconversion, and seroresponse, were applied to evaluate vaccine efficacy. RESULTS: There were 43, 84, and 71 patients in the unvaccinated, one-dose, and two-dose vaccination groups, respectively. At 4-8 weeks after vaccination, seroprotection rates in the one- and two-dose group for H1N1, H3N2, and B ranged from 82.6-95.8%, 97.4-100%, and 73.9-100%, respectively. The concomitant seroconversion and GMT fold-increases nearly met the suggested criteria for vaccine efficacy for the elderly population. Although the seroprotection rates for all of the groups were adequate, the seroconversion and GMT fold-increase at 20 weeks after vaccination did not meet the criteria for vaccine efficacy. The two-dose regimen had a higher probability of achieving seroprotection for B strains (Odds ratio: 3.5, 95% confidence interval (1.30-9.40)). No significant differences in vaccine efficacy were found between early (stage 1-3) and late (stage 4-5) stage CKD. CONCLUSIONS: The standard one-dose vaccination can elicit sufficient protective antibodies. The two-dose regimen induced a better immune response when the baseline serum antibody titer was low. Monitoring change in antibody titers for a longer duration is warranted to further determine the current vaccine strategy in CKD-ND population.
RCT Entities:
BACKGROUND: Non-dialysis-dependent chronic kidney disease (CKD-ND) patients are recommended to receive a one-dose influenza vaccination annually. However, studies investigating vaccine efficacy in the CKD-ND population are still lacking. In this study, we aimed to evaluate vaccine efficacy between the one-dose and two-dose regimen and among patients with different stages of CKD throughout a 20-week follow-up period. METHODS: We conducted a single-center, non-randomized, open-label, controlled trial among patients with all stages of CKD-ND. Subjects were classified as unvaccinated, one-dose, and two-dose groups (4 weeks apart) after enrollment. Serial changes in immunological parameters (0, 4, 8, and 20 weeks after enrollment), including seroprotection, geometric mean titer (GMT), GMT fold-increase, seroconversion, and seroresponse, were applied to evaluate vaccine efficacy. RESULTS: There were 43, 84, and 71 patients in the unvaccinated, one-dose, and two-dose vaccination groups, respectively. At 4-8 weeks after vaccination, seroprotection rates in the one- and two-dose group for H1N1, H3N2, and B ranged from 82.6-95.8%, 97.4-100%, and 73.9-100%, respectively. The concomitant seroconversion and GMT fold-increases nearly met the suggested criteria for vaccine efficacy for the elderly population. Although the seroprotection rates for all of the groups were adequate, the seroconversion and GMT fold-increase at 20 weeks after vaccination did not meet the criteria for vaccine efficacy. The two-dose regimen had a higher probability of achieving seroprotection for B strains (Odds ratio: 3.5, 95% confidence interval (1.30-9.40)). No significant differences in vaccine efficacy were found between early (stage 1-3) and late (stage 4-5) stage CKD. CONCLUSIONS: The standard one-dose vaccination can elicit sufficient protective antibodies. The two-dose regimen induced a better immune response when the baseline serum antibody titer was low. Monitoring change in antibody titers for a longer duration is warranted to further determine the current vaccine strategy in CKD-ND population.
Authors: Matteo Mombelli; Nils Rettby; Matthieu Perreau; Manuel Pascual; Giuseppe Pantaleo; Oriol Manuel Journal: Vaccine Date: 2018-09-01 Impact factor: 3.641
Authors: Elisa Cordero; Teresa A Aydillo; Ana Perez-Ordoñez; Julian Torre-Cisneros; Rosario Lara; Carmen Segura; Miguel A Gentil; Miguel A Gomez-Bravo; Ernesto Lage; Jeronimo Pachon; Pilar Perez-Romero Journal: Transplantation Date: 2012-04-27 Impact factor: 4.939
Authors: Jeffrey C Kwong; Priya P Vasa; Michael A Campitelli; Steven Hawken; Kumanan Wilson; Laura C Rosella; Therese A Stukel; Natasha S Crowcroft; Allison J McGeer; Lorne Zinman; Shelley L Deeks Journal: Lancet Infect Dis Date: 2013-06-28 Impact factor: 25.071
Authors: Cornelia Adlhoch; Joana Gomes Dias; Isabelle Bonmarin; Bruno Hubert; Amparo Larrauri; Jesús A Oliva Domínguez; Concepción Delgado-Sanz; Mia Brytting; Annasara Carnahan; Odette Popovici; Emilia Lupulescu; Joan O'Donnell; Lisa Domegan; Arianne B Van Gageldonk-Lafeber; Adam Meijer; Jan Kynčl; Pavel Slezák; Raquel Guiomar; Carlos M Orta Gomes; Theresia Popow-Kraupp; Ján Mikas; Edita Staroňová; Jackie M Melillo; Tanya Melillo; Niina Ikonen; Outi Lyytikäinen; René Snacken; Pasi Penttinen Journal: Open Forum Infect Dis Date: 2019-10-29 Impact factor: 3.835
Authors: Michael Paal; Florian M Arend; Tobias Lau; Sandra Hasmann; Daniela Soreth-Rieke; Johanna Sorodoc-Otto; Wilke Beuthien; Julia Krappe; Marcell Toepfer; Gero von Gersdorff; Norbert Thaller; Simon Rau; Bernd Northoff; Daniel Teupser; Mathias Bruegel; Michael Fischereder; Ulf Schönermarck Journal: Clin Kidney J Date: 2021-07-06
Authors: Louise Füessl; Tobias Lau; Isaac Lean; Sandra Hasmann; Bernhard Riedl; Florian M Arend; Johanna Sorodoc-Otto; Daniela Soreth-Rieke; Marcell Toepfer; Simon Rau; Haxhrije Salihi-Halimi; Michael Paal; Wilke Beuthien; Norbert Thaller; Yana Suttmann; Gero von Gersdorff; Ron Regenauer; Anke von Bergwelt-Baildon; Daniel Teupser; Mathias Bruegel; Michael Fischereder; Ulf Schönermarck Journal: Vaccines (Basel) Date: 2022-04-13